TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
Project Grant for Development of Company’s Lead Clinical Program
Helsinki, Finland – 14 Feb 2024: TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has been selected by the U.S. Department of Defense (DOD), America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset (1).
